Palisade Bio Stock Performance
| PALI Stock | USD 2.40 0.04 1.64% |
The company holds a Beta of -0.87, which implies possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Palisade Bio are expected to decrease slowly. On the other hand, during market turmoil, Palisade Bio is expected to outperform it slightly. At this point, Palisade Bio has a negative expected return of -0.44%. Please make sure to check Palisade Bio's potential upside, as well as the relationship between the daily balance of power and price action indicator , to decide if Palisade Bio performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Palisade Bio has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's essential indicators remain fairly strong which may send shares a bit higher in December 2024. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Actual Historical Performance (%)
One Day Return (3.14) | Five Day Return 1.65 | Year To Date Return (71.54) | Ten Year Return (100.00) | All Time Return (100.00) |
Last Split Factor 1:15 | Dividend Date 2019-07-18 | Last Split Date 2024-04-08 |
1 | Palisade Bio Reports Data Demonstrating PDE4B Expression in Patient Cohorts Could be Utilized as a Potential Marker for Patient Stratification | 09/05/2024 |
2 | Palisade Bio Provides Update on Progress Toward Launch of Phase 1 Human Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis | 09/25/2024 |
3 | Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis | 10/10/2024 |
4 | Acquisition by Diaz Stephanie of 9580 shares of Palisade Bio at 1.6 subject to Rule 16b-3 | 10/23/2024 |
5 | ARMISTICE CAPITAL, LLC Acquires Shares in Palisade Bio Inc - GuruFocus.com | 11/14/2024 |
6 | Disposition of 4558 shares by Jones Mitchell Lawrence of Palisade Bio subject to Rule 16b-3 | 11/18/2024 |
7 | Brookline Capital Initiates Coverage of Palisade Bio with Buy Recommendation - MSN | 11/20/2024 |
8 | Palisade Bio Now Covered by Brookline Capital Management | 11/22/2024 |
| Begin Period Cash Flow | 12.4 M |
Palisade |
Palisade Bio Relative Risk vs. Return Landscape
If you would invest 344.00 in Palisade Bio on August 27, 2024 and sell it today you would lose (104.00) from holding Palisade Bio or give up 30.23% of portfolio value over 90 days. Palisade Bio is currently does not generate positive expected returns and assumes 4.935% risk (volatility on return distribution) over the 90 days horizon. In different words, 43% of stocks are less volatile than Palisade, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Palisade Bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Palisade Bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Palisade Bio, and traders can use it to determine the average amount a Palisade Bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0895
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | PALI |
Estimated Market Risk
| 4.93 actual daily | 43 57% of assets are more volatile |
Expected Return
| -0.44 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.09 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Palisade Bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Palisade Bio by adding Palisade Bio to a well-diversified portfolio.
Palisade Bio Fundamentals Growth
Palisade Stock prices reflect investors' perceptions of the future prospects and financial health of Palisade Bio, and Palisade Bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Palisade Stock performance.
| Return On Equity | -1.1 | ||||
| Return On Asset | -0.59 | ||||
| Current Valuation | (3.95 M) | ||||
| Shares Outstanding | 1.33 M | ||||
| Price To Earning | 0.16 X | ||||
| Price To Book | 0.56 X | ||||
| Price To Sales | 14.03 X | ||||
| Revenue | 250 K | ||||
| EBITDA | (12.28 M) | ||||
| Net Income | (12.3 M) | ||||
| Cash And Equivalents | 5 M | ||||
| Cash Per Share | 0.23 X | ||||
| Total Debt | 369 K | ||||
| Debt To Equity | 0.23 % | ||||
| Current Ratio | 2.59 X | ||||
| Book Value Per Share | 18.30 X | ||||
| Cash Flow From Operations | (11.13 M) | ||||
| Earnings Per Share | (13.26) X | ||||
| Market Capitalization | 3.73 M | ||||
| Total Asset | 14.05 M | ||||
| Retained Earnings | (121.51 M) | ||||
| Working Capital | 10.74 M | ||||
About Palisade Bio Performance
By evaluating Palisade Bio's fundamental ratios, stakeholders can gain valuable insights into Palisade Bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Palisade Bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Palisade Bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -2.8 K | -3 K | |
| Return On Tangible Assets | (0.88) | (0.92) | |
| Return On Capital Employed | (1.14) | (1.20) | |
| Return On Assets | (0.88) | (0.92) | |
| Return On Equity | (1.09) | (1.14) |
Things to note about Palisade Bio performance evaluation
Checking the ongoing alerts about Palisade Bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Palisade Bio help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Palisade Bio generated a negative expected return over the last 90 days | |
| Palisade Bio has high historical volatility and very poor performance | |
| Palisade Bio has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 250 K. Net Loss for the year was (12.3 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Palisade Bio currently holds about 5 M in cash with (11.13 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.23. | |
| Palisade Bio has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Palisade Bio Now Covered by Brookline Capital Management |
- Analyzing Palisade Bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Palisade Bio's stock is overvalued or undervalued compared to its peers.
- Examining Palisade Bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Palisade Bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Palisade Bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Palisade Bio's stock. These opinions can provide insight into Palisade Bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Palisade Stock analysis
When running Palisade Bio's price analysis, check to measure Palisade Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Palisade Bio is operating at the current time. Most of Palisade Bio's value examination focuses on studying past and present price action to predict the probability of Palisade Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Palisade Bio's price. Additionally, you may evaluate how the addition of Palisade Bio to your portfolios can decrease your overall portfolio volatility.
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |